Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis

Journal of Clinical Pharmacology

Volumn 37, Issue 5, 1997, Pages 416-425

  Henderson, George N ^a   Curry, Stephen H ^b,d   Derendorf, Hartmut ^b   Wright, Elizabeth C ^c,e   Stacpoole, Peter W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d Astra Arcus USA   (United States)

^e NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROLACTIC ACID; CYCLOHEXANE; DICHLOROACETIC ACID; LACTIC ACID; PLACEBO; TRICHLOROACETIC ACID;

ADULT; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0030986217     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04319.x     Document Type: Review

References (28)

1. Stacpoole PW: The pharmacology of dichloroacetate. Metabolism 1989;38:1124-1144.
2. Stacpoole PW, Herman EM, Curry SH, Baumgartner TG, Misbin RL: Treatment of lactic acidosis with dichloroacetate. N Engl J Med 1983;309:390-396.
3. Stacpoole PW, Lorenz AC, Thomas RG, Harman EM: Dichloroacetate in the treatment of lactic acidosis. Ann Intern Med 1988;108:58-63.
4. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, et al: A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med 1992;327:1564-1569.
5. Curry SH, Chu P-I, Baumgartner TG, Stacpoole PW: Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin Pharmacol Ther 1985;37:89-93.
6. Lukas G, Vyas KH, Brindle SD, Le Sher AR, Wagner WE: Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. J Pharm Sci 1980;69:419-421.
7. Wells PG, Moore GW, Rabin D, Wilkinson GR, Oates JA, Stacpoole PW: Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. Diabetologia 1980; 19:109-113.
8. Curry SH, Lorenz A, Chu P-I, Limacher M, Stacpoole PW: Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. Biopharm Drug Disp 1991; 12:375-390.
9. Curry SH, Lorenz A, Henderson GH, Mars DR, Stacpoole PW: Hemodialysis studies with dichloroacetate. Eur J Clin Pharmacol 1991;40:613-617.
10. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, et al: Natural history and course of acquired lactic acidosis in adults. Am J Med 1994;97:47-54.
11. Stacpoole PW, Harwood HJ Jr, Cameron D, Curry SH, Schnedider M, Alvarez I, Sauberlich HE: Chronic toxicity of dichloroacetate: possible relation to thiamine deficiency in rats. Fund Appl Toxicol 1990;14:327-337.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: An evaluation of outcome from intensive care in major medical centers. Ann Intern Med 1986;104:410-418.
13. Chu PI, Curry SH, Baumgartner TG, Henderson GH, Stacpoole PW: Preparation and stability of intravenous solutions of sodium dichloroacetate (DCA). J Parenteral Sci Technol 1992;46:16-18.
14. Akcay T, Rose GA: The real and apparent plasma oxalate. Clin Chim Acta 1980;101:305-311.
15. Akaike H: A Bayesian analysis of the minimum AIC procedure. Ann Inst Statist Math Part A 1978:30:914.
16. Torres-Molina F, Peris-Ribera JE, Garcia-Carbonnell MC, Aristorena JC, Granero L, Pla-Delfina JM: Nonlinearities in amoxycillin pharmacokinetics, I: disposition studies in the rat. Biopharm Drug Disp 1992;13:23-38.
17. Dawson-Saunders B, Trapp RG: Basic and Clinical Biostatistics. Englewood Cliffs, NJ: Prentice Hall, 1990.
18. SAS Institute, Inc.: SAS/STAT User's Guide, Release 6.03. Cary, NC: SAS Institute, 1988.
19. SAS Institute, Inc.: SAS Technical Report P-200, SAS/STAT Software: CALIS and Logistic Procedures, Release 6.04. Cary, NC: SAS Institute, 1990.
20. Stacpoole PW, Moore GW, Kornhauser DM: Metabolic effects of dichloroacetate in patients with diabetes mellitus and hyperlipoproteinemia. N Engl J Med 1978;298:526-530.
21. Saville BA, Gray MR, Tam YK: Evidence for lidocaine-induced enzyme inactivation. J Pharm Sci 1989;78:1003-1008.
22. Bauer LA, Brown T, Gibaldi M, Hudson L, Nelson S, Raisys V, Shea J: Influence of long-term infusions on lidocaine kinetics. Clin Pharmacol Ther 1982;31:433-437.
23. Bax ND, Tucker GT, Woods HF: Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Pharmacokinet Biopharm 1980;10:353-361.
24. Labout JJM, Thijssen CT, Keijser GGJ, Hespe W: Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol 1982;21:343-350.
25. Bast A, Noordhoek J: Spectral interaction of orphenadrine and its metabolites with oxidized and reduced hepatic microsomal cytochrome P-450 in the rat. J Biochem Pharmacol 1982;31:2745-2753.
26. Ortiz de Montellano PR, Correia MA: Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Ann Rev Pharmacol Toxicol 1983;23:481-503.
27. Gray MR, Tam YK: Pharmacokinetics of drugs that inactivate metabolic enzymes. J Pharm Sci 1991;80:121-127.
28. Franklin MR: Ligand complexes generated during cytochrome P-450 dependent metabolism (abstract). Adv Exper Med Biol 1981;136A:165-177.